R. B. Lorenzo, L. S. Lorenzo, and A. González-Martín, “Will the carboplatin-paclitaxel-bevacizumab combination become the preferred option as the first line in advanced cervical cancer? A small experience from a single oncologic Center:  ”, CBN, vol. 5, no. 1, pp. 21–24, Apr. 2017.